Thoratec Corporation

Skip to content

Overview

Webcast ImageWebcast
Thoratec Corporation at Morgan Stanley Healthcare Conference (Replay)
09/10/14 at 12:55 p.m. ET
THOR (Common Stock)
Price26.14Change- 0.26
Volume903,664% Change0.98%
09/19/2014 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
09/09/14Thoratec Announces Start Of Heartmate III™ U.S. Clinical Trial
PLEASANTON, Calif., Sept. 9, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun to enroll patients in the HeartMate III™ U.S. clinical trial.  "We are excited to continue our recent pipeline progress with the start of the U.S. clinical trial for HeartMate III," said Gary F. Burbach, President and Chief Executive Officer.  "Our innovativ... 
Printer Friendly Version
08/29/14Thoratec Presentation At Morgan Stanley Healthcare Conference To Be Webcast
PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Ti... 
Printer Friendly Version
08/06/14Thoratec® Reports Second Quarter 2014 Results
- Revenue of $118.1 million for the second quarter of 2014 - GAAP Net Income per Diluted Share of $0.30, and Non-GAAP Net Income per Diluted Share of $0.43 - Company adjusts full-year 2014 guidance for revenue to a range of $455 million to $470 million and for net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis - HeartMate III™ and HeartMate PHP™ begin CE Mark Trials; FDA grants conditional approval to start HeartMate III U.S. IDE trial ... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.